| HLT |
Report |
System-wide comparable RevPAR growth |
MISS |
pred ~2.2% vs. cons 2.5%. |
MEDIUM |
| HLT |
Report |
Adjusted EBITDA |
IN-LINE |
pred ~$1.028B vs. cons $1.030B. |
MEDIUM |
| HLT |
Report |
Adjusted EPS |
IN-LINE |
pred ~$2.23 vs. cons $2.25. |
MEDIUM |
| HLT |
Guide |
System-wide comparable RevPAR growth |
UNCHANGED |
guide ~2.5% midpoint vs. cons 2.5% (FY2026). |
MEDIUM |
| HLT |
Guide |
Adjusted EBITDA |
UNCHANGED |
guide ~$4.040B midpoint vs. cons $4.050B (FY2026). |
MEDIUM |
| HLT |
Guide |
Adjusted EPS |
LOWER |
guide ~$8.85 midpoint vs. cons $8.90 (FY2026). |
LOW |
| HLT |
Guide |
Net unit growth |
UNCHANGED |
guide ~6.5% midpoint vs. cons 6.5% (FY2026). |
HIGH |
| HLT |
Guide |
Capital return |
UNCHANGED |
guide ~$3.50B vs. cons $3.50B (FY2026). |
MEDIUM |
| HLT |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| HLT |
Return |
5-day cumulative residual |
-1.0% (FADE) |
The initial -2.5% residual selloff should fade toward -1.0% over five days: a ~2.2% RevPAR print versus 2.5% consensus is disappointing, but retained ~2.5% FY2026 RevPAR and ~$4.040B EBITDA frameworks limit out-period estimate cuts. |
MEDIUM |